Partner With Us
At Transcripta Bio, we work with leading biotechnology companies, research centers, and patient foundations to bring new small-molecule therapies to the clinic at extraordinary speed and efficiency.
Lead Candidates
Every partnership starts with the goal of value creation by drawing on the Transcripta Drug-Gene Atlas, with hundreds of millions of proprietary experiments already completed to jump-start the collaboration. Before each program begins, we have a complete map of every target gene of interest and how it is affected by thousands of compounds. With hundreds of already-identified opportunities and the target certainty of human genetics, Transcripta is uniquely able to achieve results for development, de-risking, and discovery of programs at high speed and high certainty.
Discover
Real and Virtual Compound Screening
Partner with Transcripta to identify potential therapeutics and achieve fast time to market:
- Immediate screening of compound libraries for thousands of indications
- Predictive Conductor AI virtual screening of novel compounds across the chemogenic space
- Identify off-target hazards and toxicity markers
- Accelerated paths to market (e.g. Orphan drugs)
- Access to screening data from similar molecules to inform experiment prioritization
As soon as 9 months (with established assays)
De-Risk
Full Compound Profiles and Alternatives
For your existing programs, partner with Transcripta to accelerate and de-risk your programs with validation data and alternatives.
- Inform compounds with a full transcriptomic profile
- Identify off-target hazards and toxicity markers
- Discover additional fast-track indications (e.g. Orphan drugs) to speed time to market
- Identify alternative compounds for multiple shots on goal
- Virtual Conductor AI screening for structural perturbations and alternatives with enhanced profiles
As soon as 3 months (with established assays)
Develop
Drug Development Partnerships
Select new programs from our Drug-Gene Atlas for clinical development partnerships:
- Review full datasets to select candidates for any transcriptomic target, with full profiles for thousands of actives
- Profiles spanning nearly every chemotype and identified root cause gene
- Heavily annotated with chemoinformatic and disease-specific data
- Enriched with experimental data from multiple cell types
- Orphan-designated fast-track indications and late-stage opportunities with accelerated path to market
- Virtual Conductor AI screening for enhanced alternatives and perturbations
As soon as 6 months to IND-enabled candidates
Transcripta Programs are High Certainty:
- 100% target certainty
- Full-genome data in one shot to assess off-target risk
- Parallel imaging revealing toxicity biomarkers in early screening
- Multiple cell models optimized for translational relevance
Transcripta Programs are Faster:
- Pre-validated data in our proprietary Drug-Gene Atlas
- Cell models and assays optimized for speed
- AI modeling suite to identify off-target effects and find novel perturbations/optimizations
- Accelerated Phase II/III assets and fast-track orphan indication opportunities
Transcripta Programs are Extraordinarily Capital Efficient:
- Leverage pre-compiled Drug-Gene Atlas data and Conductor AI models
- Validation across all genetic indications at once
- Substantial regulatory and clinical efficiency advantages with accelerated assets and Orphan Drug indications
- Priority Review Voucher potential
